Published in Physician Law Weekly, October 20th, 2004
ID Biomedical's proprietary cell culture-based manufacturing process is being developed as a possible future replacement to the classical egg-based manufacturing process currently used by all flu vaccine manufacturers, including ID Biomedical.
The technology has particular application to manufacturing vaccine in the event of an influenza pandemic. This grant will allow ID Biomedical to further develop and conduct early-stage human trials of its cell culture-based influenza vaccine.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Physician Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.